A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

María Mar Sánchez-Fernández; María José Fernández-Serrano; Antonio S. Moreno-Salazar; Pedro L. Quirós-Ganga; Gustavo A. Reyes del Paso

doi:10.12659/MSM.940409

19 June 2023 : Clinical Research

A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

María Mar Sánchez-Fernández^1ABCDEF*, María José Fernández-Serrano^2ACDEFG, Antonio S. Moreno-Salazar^3ADEF, Pedro L. Quirós-Ganga^4ABDEF, Gustavo A. Reyes del Paso

^5ACDEF

DOI: 10.12659/MSM.940409

Med Sci Monit 2023; 29:e940409

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Means (±SD) of cognitive variables during the first and second evaluations (pre- and post-hemodialysis evaluations in end-stage renal disease patients treated with hemodialysis) for which significant changes were observed. Results of within-subject analysis are also included.

Domain	Test	Dep. Var.	Group	Mean±SD Pre	Mean±SD Post	F (1,83)	p	ηp2
Visual memory	Rey-Osterrieth Complex Figure (ROCF)	Memory execution	ESRD-HD	16.85±6.14	22.53±6.21	166.35	<0.0001	0.667
Visual memory	Rey-Osterrieth Complex Figure (ROCF)	Memory execution	HP	19.01±4.71	24.89±5.90	166.35	<0.0001	0.667
Verbal memory	Verbal Learning Test Spain-Complutense (TAVEC)	RLCP	ESRD-HD	9.12±3.16	11.67±2.79	109.34	<0.0001	0.568
		RLCP	HP	11.12±2.71	13.38±2.87	109.34	<0.0001	0.568
		RLLP	ESRD-HD	9.47±2.98	11.88±2.87	107.66	<0.0001	0.565
		RLLP	HP	11.86±2.67	13.64±2.54	107.66	<0.0001	0.565
		RIAT	ESRD-HD	46.65±8.45	57.60±11.37	182.67	<0.0001	0.688
		RIAT	HP	54.43±8.17	65.60±10.63	182.67	<0.0001	0.688
		Discriminability	ESRD-HD	91.61±5.57	94.05±3.90	25.92	<0.0001	0.238
		Discriminability	HP	93.57±6.51	95.92±4.68	25.92	<0.0001	0.238
Sustained and selective attention	D2	TCA	ESRD-HD	125.12±34.73	144.91±41.08	128.23	<0.0001	0.607
		TCA	HP	144.17±36.09	169.74±37.27	128.23	<0.0001	0.607
		TOT	ESRD-HD	318.14±79.57	365.81±88.21	145.81	<0.0001	0.637
		TOT	HP	365.74±82.47	408.10±87.68	145.81	<0.0001	0.637
		CON	ESRD-HD	122.14±36.65	141.37±44.85	116.89	<0.0001	0.585
		CON	HP	142.88±36.61	163.81±38.06	116.89	<0.0001	0.585
Processing speed	Trail Making Test A (TMT-A)	C2	ESRD-HD	46.77±18.94	41.77±17.61	13.33	<0.0001	0.138
		C2	HP	38.48±13.37	31.69±12.73	13.33	<0.0001	0.138
		C3	ESRD-HD	58.74±29.66	51.12±26.83	17.49	<0.0001	0.174
		C3	HP	41.86±16.49	34.31±14.18	17.49	<0.0001	0.174
	Stroop	C1	ESRD-HD	33.95±6.73	31.81±6.18	20.83	<0.0001	0.203
		C1	HP	29.36±4.77	28.21±4.80	20.83	<0.0001	0.203
		C2	ESRD-HD	23.60±5.54	22.31±3.63	8.20	0.005	0.091
		C2	HP	20.31±2.97	19.88±3.16	8.20	0.005	0.091
	Five Digit Test (5DT)	C2	ESRD-HD	23.00±4.24	21.88±3.80	17.92	<0.0001	0.178
	Five Digit Test (5DT)	C2	HP	21.17±3.72	20.26±3.64	17.92	<0.0001	0.178
	D2	TR	ESRD-HD	339.95±80.75	388.79±87.60	111.74	<0.0001	0.574
	D2	TR	HP	384.29±80.59	421.33±87.16	111.74	<0.0001	0.574
SD – standard deviation; ESRD hemodialysis – end-stage renal disease patients treated with hemodialysis; HP – healthy participants.

Back to the Article

A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodialysis in Southern Spain

Your Privacy